But due to their detection ratios, P/LP variants in BRCA1/2 and other homologue recombination repair genes represent an important indication for PARP inhibitor therapy in breast, ovarian, pancreatic, and prostate cancer [1]. This evidence concerns the gene BRCA1 and prostate cancer.